Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC in Combination wit
Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress
Did You Miss These Top Stories in Healthcare?
Last week's most exciting healthcare news: Exelixis nets a win, and Colorado takes aim at health insurers.
Exelixis, Inc. Earnings: Riding the Meteor
The biotech is still burning cash, but with data in hand, there's an opportunity for a solid revenue stream shortly.
6 Stocks That Could Double In 2016
If you have some extra cash and want to take a chance, these six stocks have the potential for excellent returns.
Are Investors Nuts To Be Short These Stocks?
Short sellers think shares in these stocks will go lower because catalysts are unlikely to support their lofty valuations.